Key result
Folic acid linked to ~27% lower Lp-PLA2 levels in CHD with hyperhomocysteinemia.
Why the study?
The effects of small doses of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in CHD patients with hyperhomocysteinemia were not well established.
Cohort (n=167)
No
Answers are grounded in this paper and cite their sources.
0.8 mg folic acid was associated with reduced Lp-PLA2 and SBP variability; hypothesis-generating and should not change practice pending RCTs.
To Investigate the recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 (LP-PLA2) and systolic blood pressure variability in coronary heart disease (CHD) patients with hyperhomocysteinemia.In this prospective cohort study, a total of 167 CHD patients with hyperhomocysteinemia were consecutively enrolled, and they were divided into Group A (without folic acid intervention, n = 99), Group B (with 0.4 mg of folic acid intervention, n = 34), Group C (0.8 mg of folic acid intervention, n = 34). General information, fasting blood glucose, and blood lipid, folic acid, homocysteine, Lp-PLA2, and blood pressure variability were compared among 3 groups. The above indicators were reviewed after 3 months of treatment.There were no statistically significant differences of age, gender, blood pressure, incidence of type 2 diabetes mellitus, fasting blood glucose, folic acid, homocysteine, Lp-PLA2, total cholesterol, 3 acyl glycerin, apolipoprotein B, lipoprotein (a), high density lipoprotein cholesterol, and low density lipoprotein cholesterol were found among 3 groups (P > .05); however, after being treated for 3 months, there was statistically significant difference in folic acid among 3 groups (P < .05), there was statistically significant difference in apolipoprotein A between Group A and Group B (t = 0.505, P = .039), and also between Group A and Group C (t = 0.052, P = .017). There were statistically significant differences in Lp-PLA2 (t = 24.320, P = .016) and systolic blood pressure variability (t = 0.154, P = .018) between Group A and Group C.For CHD patients with hyperhomocysteinemia, the higher dose (0.8 mg) of folic acid supplement was beneficial for increasing the apolipoprotein A, reducing the Lp-PLA2, and improving the systolic blood pressure variation, which might help to improve the prognosis in these patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a cohort in Coronary heart disease with hyperhomocysteinemia (n=167). Folic acid vs. No folic acid intervention was evaluated on Lipoprotein-associated phospholipase A2 (LP-PLA2) level at 3 months (umol/L) (p=0.016). Supplementation with of folic acid reduced lipoprotein-associated phospholipase A2 levels and improved systolic blood pressure variability compared to standard care alone in patients with coronary heart disease and hyperhomocysteinemia.
Synapse has enriched 10 related papers. Consider them for comparative context: